Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In One Stroke, Retrophin Acquires And Licenses Assets For Autism And Schizophrenia, Doubles Down On Oxytocin

This article was originally published in The Pink Sheet Daily

Executive Summary

Retrophin, the former rare disease specialist, announced an agreement to acquire Kyalin Biosciences, whose lead candidate is a synthetic oxytocin formulation for autism. On the same day, it licensed another intranasal formulation of oxytocin from Novartis, market-ready for an obstetric indication.

You may also be interested in...



Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans

The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.

Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?

Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.

Ketamine May Shake Up The Treatment Of Major Depression

Pharmas have shied away from the challenging antidepressant market in recent years, but two late-stage ketamine-like candidates are leading the pack of novel agents in development.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075157

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel